These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 27160948)

  • 21. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.
    Tang DH; Colayco DC; Khalaf KM; Piercy J; Patel V; Globe D; Ginsberg D
    BJU Int; 2014 Mar; 113(3):484-91. PubMed ID: 24528881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study.
    Mattiasson A; Masala A; Morton R; Bolodeoku J;
    BJU Int; 2010 Apr; 105(8):1126-35. PubMed ID: 19818077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire.
    Piault E; Evans CJ; Espindle D; Kopp Z; Brubaker L; Abrams P
    Neurourol Urodyn; 2008; 27(3):179-90. PubMed ID: 17565727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study.
    Sexton CC; Coyne KS; Thompson C; Bavendam T; Chen CI; Markland A
    J Am Geriatr Soc; 2011 Aug; 59(8):1465-70. PubMed ID: 21718275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
    Chughtai B; Dunphy C; Lee R; Lee D; Sheth S; Marks L; Kaplan SA; Te AE
    Can J Urol; 2014 Apr; 21(2):7217-21. PubMed ID: 24775575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Symptom severity and patient perceptions in overactive bladder: how are they related?
    Homma Y; Gotoh M
    BJU Int; 2009 Oct; 104(7):968-72. PubMed ID: 19338560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defining response and non-response to treatment in patients with overactive bladder: a systematic review.
    Goldman HB; Wyndaele JJ; Kaplan SA; Wang JT; Ntanios F
    Curr Med Res Opin; 2014 Mar; 30(3):509-26. PubMed ID: 24164097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Redefining response in overactive bladder syndrome.
    Payne CK; Kelleher C
    BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation study of the Self-Assessment Goal Achievement (SAGA) questionnaire for lower urinary tract symptoms.
    Brubaker L; Piault EC; Tully SE; Evans CJ; Bavendam T; Beach J; Yeh Y; Kopp ZS; Khullar V; Kelleher CJ; Trocio J
    Int J Clin Pract; 2013 Apr; 67(4):342-50. PubMed ID: 23521326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychosocial factors related to the use of InterStim® for the treatment of refractory overactive bladder.
    Levin PJ; Siddiqui NY; Wu JM; Amundsen CL
    Female Pelvic Med Reconstr Surg; 2014; 20(5):272-5. PubMed ID: 25181377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors influencing efficacy endpoints in clinical trials for new oral medicinal treatments for overactive bladder: a systematic literature review and meta-analysis.
    Iino S; Kaneko M; Narukawa M
    Int Urol Nephrol; 2018 Jun; 50(6):1021-1030. PubMed ID: 29651695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of caffeinated versus decaffeinated drinks on overactive bladder: a double-blind, randomized, crossover study.
    Wells MJ; Jamieson K; Markham TC; Green SM; Fader MJ
    J Wound Ostomy Continence Nurs; 2014; 41(4):371-8. PubMed ID: 24988515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis.
    Mostafaei H; Janisch F; Mori K; Quhal F; Pradere B; Hajebrahimi S; Roehrborn CG; Shariat SF
    Eur Urol Focus; 2022 Jan; 8(1):239-252. PubMed ID: 33674256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overactive Bladder Symptoms in Female Health Profession Students: Bladder Diary Characteristics and Impact of Symptoms on Health-Related Quality of Life.
    Reisch R; Rutt R; Dockter M; Sanders S
    J Womens Health (Larchmt); 2018 Feb; 27(2):156-161. PubMed ID: 28953429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
    Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
    Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.